KAYLA DAVIS: Open Payments
NPI 1255689881 · WACO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$705 in 46 payments from 14 companies in 2025. Trend: 2023 $423 · 2024 $769 · 2025 $705
Food & beverage: $705
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 16 | $142 |
| GlaxoSmithKline, LLC. | 5 | $89 |
| Novo Nordisk Inc | 4 | $75 |
| Sumitomo Pharma America, Inc. | 2 | $52 |
| Abbott Laboratories | 2 | $51 |
| PFIZER INC. | 3 | $50 |
| Exact Sciences Corporation | 3 | $47 |
| AstraZeneca Pharmaceuticals LP | 2 | $37 |
| Lilly USA, LLC | 2 | $36 |
| Dexcom, Inc. | 2 | $35 |
Products named: OTEZLA, TRELEGY ELLIPTA, GEMTESA, ETERNA, ELIQUIS, Wegovy, FARXIGA, Dexcom G6 Transmitter.
Industry payments across TX — which companies pay providers there.
